In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...

Akeega’s is now FDA indicated for mCSPC and mCRPC, widening the drug’s future market potential across the prostate cancer ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

Researchers have discovered a key mechanism that makes prostate cancer cells resistant to the latest drugs, solving a ...

Monte Rosa Therapeutics Inc. plans a signal-verifying phase II trial next year after making known the positive interim data from an ongoing phase I/II trial testing molecular glue degrader MRT-2359 in ...

The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...

Investing.com -- Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 3.5% after the company announced positive interim data from its Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide ...

Two large deals and an acquisition, all totaling about $4.64 billion, are helping close out a strong year. Yarrow Bioscience Inc. cut a potentially $1.36 billion deal with Shanghai Scizeng Medical ...

UCSF researchers showed that estrogen can turn on pain signals in the gut, offering new insights into conditions like ...